Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.

Cancer Res. 2006 Jul 1;66(13):6732-40.

2.

Expression of single-chain Fv-Fc fusions in Pichia pastoris.

Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD.

J Immunol Methods. 2001 May 1;251(1-2):123-35.

PMID:
11292488
3.

186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.

Kotts CE, Su FM, Leddy C, Dodd T, Scates S, Shalaby MR, Wirth CM, Giltinan D, Schroff RW, Fritzberg AR, Shepard HM, Slamon DJ, Hutchins BM.

Cancer Biother Radiopharm. 1996 Apr;11(2):133-44.

PMID:
10851530
4.

Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.

Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C.

Clin Immunol Immunopathol. 1995 Feb;74(2):185-92.

PMID:
7828373
5.

Towards an immunotherapy for p185HER2 overexpressing tumors.

Carter P, Rodrigues ML, Lewis GD, Figari I, Shalaby MR.

Adv Exp Med Biol. 1994;353:83-94. No abstract available.

PMID:
7985544
6.

Butylated hydroxyanisole specifically inhibits tumor necrosis factor-induced cytotoxicity and growth enhancement.

Brekke OL, Shalaby MR, Sundan A, Espevik T, Bjerve KS.

Cytokine. 1992 Jul;4(4):269-80.

PMID:
1515551
7.

Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.

Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.

Int J Cancer Suppl. 1992;7:45-50.

PMID:
1428403
8.

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.

Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, Carter P.

J Exp Med. 1992 Jan 1;175(1):217-25.

9.

Cytokine-associated tissue injury and lethality in mice: a comparative study.

Shalaby MR, Halgunset J, Haugen OA, Aarset H, Aarden L, Waage A, Matsushima K, Kvithyll H, Boraschi D, Lamvik J, et al.

Clin Immunol Immunopathol. 1991 Oct;61(1):69-82.

PMID:
1959240
10.

Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors.

Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T.

J Exp Med. 1990 Nov 1;172(5):1517-20.

11.
12.

Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo.

Shalaby MR, Waage A, Aarden L, Espevik T.

Clin Immunol Immunopathol. 1989 Dec;53(3):488-98.

PMID:
2805453
13.

Tumor necrosis factor-alpha-associated uterine endothelial injury in vivo. Influence of dietary fat.

Shalaby MR, Laegreid WW, Ammann AJ, Liggitt HD.

Lab Invest. 1989 Nov;61(5):564-70.

PMID:
2554060
14.

Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes.

Smeland EB, Blomhoff HK, Funderud S, Shalaby MR, Espevik T.

J Exp Med. 1989 Oct 1;170(4):1463-8.

15.

Cytokine regulation of interleukin 6 production by human endothelial cells.

Shalaby MR, Waage A, Espevik T.

Cell Immunol. 1989 Jul;121(2):372-82.

PMID:
2500254
16.

Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha.

Shalaby MR, Fendly B, Sheehan KC, Schreiber RD, Ammann AJ.

Transplantation. 1989 Jun;47(6):1057-61.

PMID:
2525289
17.
18.

The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction.

Shalaby MR, Espevik T, Rice GC, Ammann AJ, Figari IS, Ranges GE, Palladino MA Jr.

J Immunol. 1988 Jul 15;141(2):499-503.

PMID:
2968403
19.

Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells.

Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, Shepard HM.

Proc Natl Acad Sci U S A. 1988 Jul;85(14):5102-6.

20.

Suppression of immune cell function in vitro by recombinant human transforming growth factor-beta.

Shalaby MR, Ammann AJ.

Cell Immunol. 1988 Apr 1;112(2):343-50.

PMID:
2965617
21.

The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vitro.

Shalaby MR, Krowka JF, Gregory TJ, Hirabayashi SE, McCabe SM, Kaufman DS, Stites DP, Ammann AJ.

Cell Immunol. 1987 Nov;110(1):140-8.

PMID:
2824064
22.

Inhibition of cytokine production by cyclosporin A and transforming growth factor beta.

Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA Jr.

J Exp Med. 1987 Aug 1;166(2):571-6.

23.

Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.

Palladino MA Jr, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS, et al.

J Immunol. 1987 Jun 1;138(11):4023-32.

PMID:
3295044
24.

Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha.

Shalaby MR, Palladino MA Jr, Hirabayashi SE, Eessalu TE, Lewis GD, Shepard HM, Aggarwal BB.

J Leukoc Biol. 1987 Mar;41(3):196-204.

PMID:
3031189
25.

Possible relationships between in vivo antitumour activity and toxicity of tumour necrosis factor-alpha.

Palladino MA Jr, Patton JS, Figari IS, Shalaby MR.

Ciba Found Symp. 1987;131:21-38. Review.

PMID:
3330012
26.

Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.

Peters PM, Ortaldo JR, Shalaby MR, Svedersky LP, Nedwin GE, Bringman TS, Hass PE, Aggarwal BB, Herberman RB, Goeddel DV, et al.

J Immunol. 1986 Oct 15;137(8):2592-8.

PMID:
3760569
27.

An overview of the history and biologic properties of tumor necrosis factors.

Shalaby MR, Pennica D, Palladino MA Jr.

Springer Semin Immunopathol. 1986;9(1):33-7. Review. No abstract available.

PMID:
3523803
28.

Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.

Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr.

J Immunol. 1985 Sep;135(3):2069-73.

PMID:
3926894
29.

In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and interleukin-2.

Shalaby MR, Svedersky LP, McKay PA, Finkle BS, Palladino MA Jr.

J Interferon Res. 1985 Fall;5(4):571-81.

PMID:
3936881
30.

Interferon gamma: more than a MAF.

Peters PM, Svedersky LP, Shalaby MR, Palladino MA Jr.

Lymphokine Res. 1985 Summer;4(3):265-73.

PMID:
3928982
31.

In vivo antiviral activity of recombinant murine gamma interferon.

Shalaby MR, Hamilton EB, Benninger AH, Marafino BJ Jr.

J Interferon Res. 1985 Spring;5(2):339-45.

PMID:
2989389
32.

Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2.

Svedersky LP, Shepard HM, Spencer SA, Shalaby MR, Palladino MA.

J Immunol. 1984 Aug;133(2):714-8.

PMID:
6203975
33.

Effects of bacteria-produced human alpha, beta, and gamma interferons on in vitro immune functions.

Shalaby MR, Weck PK, Rinderknecht E, Harkins RN, Frane JW, Ross MJ.

Cell Immunol. 1984 Apr 1;84(2):380-92.

PMID:
6231112
34.
35.
36.

Canine surface active material and pulmonary lymphocyte function. Studies with mixed-lymphocyte culture.

Ansfield MJ, Kaltreider HB, Benson BJ, Shalaby MR.

Exp Lung Res. 1980 Mar;1(1):3-11.

PMID:
6453001
37.

An indirect assay for canine leukocyte migration inhibitory factor (LIF): demonstration of its species specificity.

Ansfield MJ, Shalaby MR, Kaltreider HB.

J Immunol Methods. 1980;34(1):43-8.

PMID:
6448271
38.
39.

Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line.

Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, Mattingly RF.

Science. 1977 Jun 24;196(4297):1456-8.

PMID:
867042
40.

Effect of Crude and Purified hCG on Lymphocyte Blastogenesis.

Pattillo RA, Shalaby MR, Hussa RO, Bahl OP, Mattingly RF.

Obstet Gynecol. 1976 May;47(5):557-61.

PMID:
1264402
41.

Graft-vs.-host reaction in tissue culture.

Auerbach R, Shalaby MR.

J Exp Med. 1973 Dec 1;138(6):1506-20.

Supplemental Content

Loading ...
Support Center